Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Fertility Solutions-Focused Progyny Stock Sinks After Soft Guidance; Analyst Says 'Can No Longer Underwrite Sustained Healthy Growth In Forecasts'

Published 10/05/2024, 19:42
Updated 10/05/2024, 21:11
© Reuters.  Fertility Solutions-Focused Progyny Stock Sinks After Soft Guidance; Analyst Says 'Can No Longer Underwrite Sustained Healthy Growth In Forecasts'
PGNY
-

Benzinga - by Vandana Singh, Benzinga Editor.

On Thursday, Progyny Inc (NASDAQ:PGNY) reported first-quarter sales of $278.1 million, up 7.6% year over year, missing the consensus of $289.46 million, primarily due to the increased number of clients and covered lives.

Fertility benefit services revenue was $169.8 million, an 8.0% increase from the $157.1 million reported in the first quarter of 2023.

Pharmacy benefit services revenue was $108.3 million, a 7.0% increase compared to the $101.2 million reported in the first quarter of 2023.

The company reported adjusted EPS of $0.39, up from $0.34 a year ago.

The company had 451 clients as of March 31, 2024, compared to 379 a year ago. Assisted Reproductive Technology (ART) cycles were 14,802 compared to 13,171 a year ago. Utilization rate was 0.53%.

“Utilization through the end of February was consistent with the record engagement we saw a year ago. However, March was modestly below our expectations, coinciding with the national conversations concerning fertility treatments and access to maternal healthcare following the Alabama Supreme Court ruling,” said Pete Anevski, CEO of Progyny.

“This, in combination with the previously-disclosed unfavorable treatment mix shift that we experienced for a limited period of time earlier in the first quarter, lowered our first quarter revenue growth rate,” Anevski added.

Guidance: Progyny expects second-quarter adjusted EPS of $0.39-$0.41 versus consensus of $0.41.

The company sees second-quarter revenue of $300 million-$310 million versus the consensus of $335.76 million.

Progyny forecasts fiscal year 2024 adjusted EPS of $1.61-$1.68 versus a consensus of $1.57, and revenue of $1.23 billion—$1.27 billion versus a consensus of $1.29 billion.

KeyBanc Capital Markets lowered the rating from Overweight to Sector Weight.

The analyst says, ‘We are becoming more weary of the company’s visibility into its revenues, utilization, and customer behavior.” The new client cohorts added will likely not meet the utilization profiles of the legacy cohorts and constricted budgets.

“While we always believed Progyny deserved a more premium multiple than where it had been trading, this was predicated on sustained healthy growth, which we longer can underwrite in our forecasts,” the KeyBanc analyst writes.

Keybanc revised revenue growth projections to around 14% for this year and approximately 10% for next year. The analyst says better utilization rates and customer trends, along with an understanding of overall business performance, are needed to regain confidence in the stock.

Price Action: PGNY shares are down 20.8% at $25.74 at last check Friday.

Latest Ratings for PGNY

DateFirmActionFromTo
Dec 2021JefferiesInitiates Coverage OnBuy
Sep 2021BerenbergInitiates Coverage OnBuy
Sep 2021BarclaysMaintainsOverweight
View More Analyst Ratings for PGNY

View the Latest Analyst Ratings

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.